Biogen (BIIB) Tops Q2 EPS by 24c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $215.50 -1.62%
Revenue Growth %: +4.3%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +4.3%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q2 EPS of $4.02, $0.24 better than the analyst estimate of $3.78. Revenue for the quarter came in at $2.46 billion versus the consensus estimate of $2.37 billion.
GUIDANCE:
Biogen sees FY2023 EPS of $15.00-$16.00, versus the consensus of $15.43.
- Total revenue Mid-single digit percentage decline
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
